FREQ
Frequency Therapeutics, Inc. [FREQ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
FREQ Stock Summary
In the News
FREQ Financial details
Company Rating
Neutral
Market Cap
10.94M
Income
-59.32M
Revenue
0
Book val./share
0.99
Cash/share
1.13
Dividend
-
Dividend %
-
Employees
46
Optionable
No
Shortable
Yes
Earnings
02 Nov 2023
P/E
-0.19
Forward P/E
-
PEG
0.06
P/S
-
P/B
0.3
P/C
0.27
P/FCF
-0.29
Quick Ratio
4.34
Current Ratio
4.42
Debt / Equity
0.04
LT Debt / Equity
-
-
-
EPS (TTM)
-1.65
EPS next Y
-
EPS next Q
-
EPS this Y
-5.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
3.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
21.46%
Inst Trans
1.58%
ROA
-128%
ROE
188%
ROC
-1.72%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.183-5.59
52W High
-
52W Low
-
RSI
65
Rel Volume
2.29
Avg Volume
135.08K
Volume
309.16K
Perf Week
29.14%
Perf Month
-
Perf Quarter
-
Perf Half Y
5.12%
-
-
-
-
Beta
0.771
-
-
Volatility
0.03%, 0.03%
Prev Close
0%
Price
0.2996
Change
3.31%
FREQ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 3.35 | 1.15 | 0.41 | 0 | |
| Net income per share | -1.59 | -1.85 | -0.82 | -2.47 | -2.33 | |
| Operating cash flow per share | -1.41 | 3.96 | -1.4 | -2.21 | -1.66 | |
| Free cash flow per share | -1.45 | 3.83 | -1.61 | -2.3 | -1.66 | |
| Cash per share | 3.5 | 27.12 | 6.83 | 3.81 | 3.26 | |
| Book value per share | -4 | -7.96 | -2.96 | 3.81 | -7.46 | |
| Tangible book value per share | -4 | 19.35 | 5.97 | 3.81 | 1.97 | |
| Share holders equity per share | -4 | -7.96 | -2.96 | 3.81 | -7.46 | |
| Interest debt per share | 0.01 | 0.58 | 1.43 | 1.35 | 1.25 | |
| Market cap | 165.23M | 151.62M | 1.14B | 176.22M | 135.04M | |
| Enterprise value | 123.04M | -65.73M | 962.9M | 142.19M | 94.89M | |
| P/E ratio | -8.62 | -9.47 | -42.9 | -2.08 | -1.66 | |
| Price to sales ratio | 0 | 5.24 | 30.75 | 12.53 | 0 | |
| POCF ratio | -9.71 | 4.43 | -25.17 | -2.32 | -2.32 | |
| PFCF ratio | -9.46 | 4.57 | -21.93 | -2.23 | -2.32 | |
| P/B Ratio | -3.42 | -2.2 | -11.92 | 1.35 | -0.52 | |
| PTB ratio | -3.42 | -2.2 | -11.92 | 1.35 | -0.52 | |
| EV to sales | 0 | -2.27 | 26.04 | 10.11 | 0 | |
| Enterprise value over EBITDA | -6.73 | 3.16 | -34.85 | -1.75 | -1.18 | |
| EV to operating cash flow | -7.23 | -1.92 | -21.31 | -1.87 | -1.63 | |
| EV to free cash flow | -7.05 | -1.98 | -18.57 | -1.8 | -1.63 | |
| Earnings yield | -0.12 | -0.11 | -0.02 | -0.48 | -0.6 | |
| Free cash flow yield | -0.11 | 0.22 | -0.05 | -0.45 | -0.43 | |
| Debt to equity | 0 | -0.05 | -0.48 | 0.35 | -0.16 | |
| Debt to assets | 0 | 0.01 | 0.17 | 0.25 | 0.35 | |
| Net debt to EBITDA | 2.31 | 10.44 | 6.31 | 0.42 | 0.5 | |
| Current ratio | 11.38 | 4.19 | 8.45 | 11.79 | 4.16 | |
| Interest coverage | -178.72 | -11.59 | 0 | -109.99 | -86.37 | |
| Income quality | 0.89 | -1.83 | 1.7 | 0.9 | 0.71 | |
| Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.07 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 1.07 | 0.73 | 2.64 | 0 | |
| Research and developement to revenue | 0 | 0.65 | 1.01 | 4.33 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | -0.03 | 0.15 | 0.04 | 0 | |
| Capex to revenue | 0 | -0.04 | -0.18 | -0.21 | 0 | |
| Capex to depreciation | -0.67 | -1.31 | -5.82 | -1.05 | 0 | |
| Stock based compensation to revenue | 0 | 0.12 | 0.27 | 1.55 | 0 | |
| Graham number | 11.96 | 18.21 | 7.4 | 14.53 | 19.76 | |
| ROIC | 0.39 | 0.27 | 1.5 | -0.41 | 0.44 | |
| Return on tangible assets | -0.43 | -0.07 | -0.1 | -0.46 | -0.67 | |
| Graham Net | -4.19 | 20.9 | 4.67 | 2.27 | 1.84 | |
| Working capital | 39.16M | 168.58M | 198.43M | 123.32M | 66.47M | |
| Tangible asset value | -48.28M | 167.36M | 192.49M | 130.82M | 69.2M | |
| Net current asset value | -49.89M | 165.5M | 152.83M | 80.21M | 35.45M | |
| Invested capital | 0 | -0.05 | -0.48 | 0.35 | -0.16 | |
| Average receivables | 80.5K | 483K | 572.5K | 242K | 296.5K | |
| Average payables | 1.43M | 1.54M | 3.36M | 4.13M | 2.93M | |
| Average inventory | 0 | 1.5M | 3.64M | 4M | 3.7M | |
| Days sales outstanding | 0 | 10.15 | 3.36 | 3.74 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 35.96 | 108.78 | 97.69 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.4 | 0.23 | 0.28 | -0.65 | 0.31 | |
| Capex per share | -0.04 | -0.12 | -0.21 | -0.08 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.55 | -0.49 | -0.55 | -0.3 | -0.31 | |
| Operating cash flow per share | -0.33 | -0.44 | -0.4 | -0.24 | 0.01 | |
| Free cash flow per share | -0.33 | -0.44 | -0.4 | -0.24 | 0.01 | |
| Cash per share | 2.82 | 3.24 | 1.89 | 1.3 | 1.13 | |
| Book value per share | 2.33 | -7.42 | 1.51 | 1.27 | 0.99 | |
| Tangible book value per share | 2.33 | 1.96 | 1.51 | 1.27 | 0.99 | |
| Share holders equity per share | 2.33 | -7.42 | 1.51 | 1.27 | 0.99 | |
| Interest debt per share | 1.26 | 1.23 | 1.14 | 0.78 | 0.04 | |
| Market cap | 63.09M | 135.76M | 17.77M | 12.39M | 13.66M | |
| Enterprise value | 63.49M | 95.61M | 16.88M | 485.08K | -26.63M | |
| P/E ratio | -0.81 | -1.95 | -0.23 | -0.29 | -0.29 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -5.35 | -8.69 | -1.26 | -1.47 | 34.85 | |
| PFCF ratio | -5.35 | -8.7 | -1.25 | -1.47 | 34.85 | |
| P/B Ratio | 0.77 | -0.52 | 0.33 | 0.27 | 0.37 | |
| PTB ratio | 0.77 | -0.52 | 0.33 | 0.27 | 0.37 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -3.41 | -5.61 | -0.93 | -0.05 | 2.1 | |
| EV to operating cash flow | -5.38 | -6.12 | -1.19 | -0.06 | -67.95 | |
| EV to free cash flow | -5.38 | -6.13 | -1.19 | -0.06 | -67.95 | |
| Earnings yield | -0.31 | -0.13 | -1.1 | -0.87 | -0.85 | |
| Free cash flow yield | -0.19 | -0.11 | -0.8 | -0.68 | 0.03 | |
| Debt to equity | 0.54 | -0.16 | 0.75 | 0.61 | 0.04 | |
| Debt to assets | 0.33 | 0.35 | 0.39 | 0.35 | 0.03 | |
| Net debt to EBITDA | -0.02 | 2.36 | 0.05 | 1.16 | 3.18 | |
| Current ratio | 5.05 | 4.16 | 3.14 | 5.81 | 4.42 | |
| Interest coverage | -77.09 | -58.32 | -72.22 | 0 | 0 | |
| Income quality | 0.6 | 0.9 | 0.72 | 0.78 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0.02 | -0.1 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.39 | 9.07 | 4.33 | 2.93 | 2.65 | |
| ROIC | -0.13 | 0.1 | -0.17 | -0.12 | -0.32 | |
| Return on tangible assets | -0.14 | -0.14 | -0.19 | -0.14 | -0.25 | |
| Graham Net | 1.29 | 1.83 | 0.52 | 0.35 | 0.87 | |
| Working capital | 80.99M | 66.47M | 47.26M | 40.05M | 32.89M | |
| Tangible asset value | 81.97M | 69.2M | 53.25M | 45.41M | 36.74M | |
| Net current asset value | 46.95M | 35.45M | 21.04M | 14.4M | 32.89M | |
| Invested capital | 0.54 | -0.16 | 0.75 | 0.61 | 0.04 | |
| Average receivables | 0 | 224.5K | 224.5K | 0 | 0 | |
| Average payables | 3.78M | 3.56M | 2.91M | 2M | 816K | |
| Average inventory | 0 | 1.85M | 1.85M | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.24 | 0.07 | -0.37 | -0.24 | -0.32 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
FREQ Frequently Asked Questions
What is Frequency Therapeutics, Inc. stock symbol ?
Frequency Therapeutics, Inc. is a US stock , located in Lexington of Ma and trading under the symbol FREQ
What is Frequency Therapeutics, Inc. stock quote today ?
Frequency Therapeutics, Inc. stock price is $0.2996 today.
Is Frequency Therapeutics, Inc. stock public?
Yes, Frequency Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 135.08K
- Market Capitalization 10.94M
- Employee 46
- CEO Mr. David L. Lucchino
- Headquarters Lexington,MA,US
- IPO Date 2019-10-03
-
Website
https://www.frequencytx.com 
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
